Decision to list medical devices supplied by Medtronic
We’re pleased to announce of a listing agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of needles and syringes products.
In summary this will result in:
- Medtronic needles and syringes products being listed on the Pharmaceutical Schedule from 1 March 2019 under a national agreement that all DHBs may purchase under (“Agreement”).
- All products contained within this agreement are expected to transition to Cardinal Health Australia 503 Pty Ltd (Cardinal Health) as part of the transition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to Cardinal Health. The transition is expected to occur early in the new year. PHARMAC, Cardinal Health and Medtronic are in discussions about transfer of relevant agreements.
- This is a non-exclusive listing agreement, DHBs would continue to be able to purchase other suppliers’ brands of needles and syringes.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 23 November 2018. No changes have been made to the listing Agreement as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- All DHB clinical staff including but not limited to:
- Allied Health staff
- Clinical Engineers
- Clinical staff working in surgical and medical units, emergency departments, intensive and critical care units, and outpatient units
- District nurses
- Perioperative staff
- Procurement Officers
- Technical staff.
Detail about this decision
In 2017 PHARMAC issued a Requests for Proposals (“RFP”) for needles and syringes.
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation processes and consulting on the provisional Agreement reached with Medtronic, PHARMAC has decided to list Medtronic’s range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule.
DHBs that purchase Medtronic’s needles and syringes must do so under the terms and conditions and at the prices included in the Agreement, from 1 March 2019. DHBs can continue to choose which needles and syringes they purchase.
Please note: All products contained within this agreement are expected to transition to Cardinal Health as part of the transition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to Cardinal Health. The transition is expected to occur early in the new year. PHARMAC, Cardinal Health and Medtronic are in discussions about transfer of relevant agreements
PHARMAC expects to consult on further agreements with suppliers of needles and syringes over the next few months.
Our response to what you told us
We’re really grateful for the time people took to respond to this consultation. A summary of the main themes raised in feedback and our responses to the feedback received, are set out below.
|Theme||PHARMAC staff comment|
Ministry of Health
Advising no technical resource impacts anticipated as a result of proposal
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.